Stelara shows efficacy in real-world study

After 52 weeks of treatment, Stelara helped induce clinical and endoscopic remission in patients with refractory Crohn’s disease, according to study results.Marisa Iborra, MD, PhD, from Hospital Universitari Politecnic La Fe in Spain, and colleagues wrote that there is little research on the long-term safety and efficacy of Stelara (ustekinumab, Janssen), using data taken from daily clinical practice.“Although these studies confirm the effectiveness and safety of ustekinumab in CD patients refractory to many treatments, the number of patients analyzed in the long-term follow-up isRead More

Share on facebook
Share on twitter
Share on linkedin